Bridging the Gap Between ACR Guidelines and Real-World RA Management

In this episode, 'Bridging the Gap Between ACR Guidelines and Real-World RA Management,' the expert rheumatologist explored the following questions:

• The American College of Rheumatology (ACR) guidelines provide a framework for rheumatoid arthritis (RA) management, but there's often a gap between what guidelines recommend and what happens in practice for RA. Where do you see the biggest disconnect, and what's driving it?

Dr. Julia Buchfuhrer examined the lag between published ACR guidelines and current clinical evidence, noting that the guideline development process typically spans several years, meaning recommendations can reflect data that is up to a decade old by the time they're implemented in practice. She discussed how the ACR guidelines themselves caution against rigid application, encouraging clinicians to rely on clinical judgment for each patient. The conversation centered on the guidelines' conditional recommendation to switch to another biologic within the same class after a tumor necrosis factor (TNF) inhibitor failure, when growing observational and randomized controlled trial data suggest patients often do better switching to a different drug class entirely.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk,' features Dr. Buchfuhrer advancing her conversation on rheumatoid arthritis and focusing on how defining remission as the treatment goal, rather than low disease activity, can influence long-term joint and systemic outcomes.